Navigation Links
Systemic Lupus Erythematosus Therapeutics (SLE) - Pipeline Assessment and Market Forecasts to 2018
Date:10/19/2011

NEW YORK, Oct. 19, 2011 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Systemic Lupus Erythematosus Therapeutics (SLE) - Pipeline Assessment and Market Forecasts to 2018

http://www.reportlinker.com/p0656881/Systemic-Lupus-Erythematosus-Therapeutics-SLE---Pipeline-Assessment-and-Market-Forecasts-to-2018.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology

Systemic Lupus Erythematosus Therapeutics (SLE) - Pipeline Assessment and Market Forecasts to 2018

Summary

GlobalData, the industry analysis specialist, has released its new report, "Systemic Lupus Erythematosus Therapeutics (SLE) - Pipeline Assessment and Market Forecasts to 2018". The report is an essential source of information and analysis on the global SLE market. The report identifies the key trends shaping and driving the global SLE market. It also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the positioning of current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global SLE sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

GlobalData estimated the global (the US, the UK, France, Germany, Italy, Spain and Japan) systemic lupus erythematosus (SLE) therapeutics market to be worth $256m in 2010 and projects it to grow at a compound annual growth rate (CAGR) of 24.7% to reach $1.6 billion in 2018. Benlysta (belimumab) was approved on March 9, 2011 by the US Food and Drug Administration (FDA) and on July 14, 2011 by the European Medicine Evaluation Agency (EMEA) in Europe for treating adult patients with active, autoantibody-positive SLE. It the drug for SLE to be approved in 50 years and is expected to drive the SLE market in the near future. Furthermore, the entry of four first-in-class (FIC) biologics, Orencia (abatacept), atacicept, epratuzumab, LY2127399 is expected to play a major role in the expansion of the SLE market by 2018.

Scope

The report provides information on the key drivers and challenges of the SLE market. Its scope includes -

- Annualized seven key SLE market (US, France, Germany, Italy, Spain, UK and Japan) revenue data from 2005 to 2010, forecast for eight years to 2018.

- Pipeline analysis data showing a split across the different phases, mechanisms of action being developed and emerging trends. Pipeline candidates fall under the following major therapeutic classes: anti-BAFF (B-cell activating factor), immunomodulator, anti-IFN-alpha, Toll-Like Receptor TLR7/TLR9 inhibitor, CD22 antigen Inhibitor, T-cell co-stimulation modulator and calcineurin inhibitor.

- Analysis of the current and future competition in the global SLE market. Key market players covered are Anthera Pharma, AstraZeneca PLC/MedImmune LLC, Active Biotech AB, Amgen Inc., Bristol-Myers Squibb Co., Biotest AG, Cephalon, Inc., Eli Lilly and Co., F. Hoffmann-La Roche Ltd/Genentech, Johnson & Johnson/Centocor, Inc, Merck KGaA/Merck Sereno, MedImmune, LLC, Neovacs SA, Onyx Pharmaceuticals and UCB Group/Immunomedics Inc.

- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.

- Key topics covered include strategic competitor assessment, market characterization, unmet need and the implications for the SLE therapeutics market.

- Analysis of key recent licensing and partnership agreements in the SLE market.

Reasons to buy

The report will enhance your decision making capability. It will allow you to -

- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline.

- Develop business strategies by understanding the trends shaping and driving the global SLE market.

- Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global SLE market in the future.

- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.

- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.

- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

- What is the next big thing in the global SLE market landscape? Identify, understand and capitalize.

1 Table of contents

1 Table of contents 3

1.1 List of Tables 5

1.2 List of Figures 6

2 Systemic Lupus Erythematosus Therapeutics - Introduction 7

2.1 Disease Overview 7

2.2 Epidemiology 7

2.3 Etiology 8

2.3.1 Genes 8

2.3.2 Environment 8

2.3.3 Hormones 8

2.4 Symptoms 8

2.5 Risk Factors 9

2.6 Diagnosis 9

2.7 Treatment and Management Pattern 10

2.7.1 Treatment Algorithm for Systemic Lupus Erythematosus 10

2.8 GlobalData Pipeline Report Guidance 12

3 Systemic Lupus Erythematosus Therapeutics - Market Characterization 13

3.1 Systemic Lupus Erythematosus Therapeutics Market Size (2005-2010) - Global 13

3.2 Systemic Lupus Erythematosus Therapeutics Market Forecast (2010-2018) - Global 15

3.3 Systemic Lupus Erythematosus Therapeutics Market Size (2005-2010) - The US 17

3.4 Systemic Lupus Erythematosus Therapeutics Market Forecast (2010-2018) - The US 18

3.5 Systemic Lupus Erythematosus Therapeutics Market Size (2005-2010) - the UK 19

3.6 Systemic Lupus ErythematosusTherapeutics Market Forecast (2010-2018) -the UK 20

3.7 Systemic Lupus Erythematosus Therapeutics Market Size (2005-2010) - France 21

3.8 Systemic Lupus Erythematosus Therapeutics Market Forecast (2010-2018) - France 22

3.9 Systemic Lupus Erythematosus Therapeutics Market Size (2005-2010) - Germany 23

3.10 Systemic Lupus Erythematosus Therapeutics Market Forecast (2010-2018) - Germany 24

3.11 Systemic Lupus Erythematosus Therapeutics Market Size (2005-2010) - Italy 25

3.12 Systemic Lupus Erythematosus Therapeutics Market Forecast (2010-2018) - Italy 26

3.13 Systemic Lupus Erythematosus Therapeutics Market Size (2005-2010) - Spain 28

3.14 Systemic Lupus Erythematosus Therapeutics Market Forecast (2010-2018) - Spain 29

3.15 Systemic Lupus Erythematosus Therapeutics Market Size (2005-2010) - Japan 30

3.16 Systemic Lupus Erythematosus Therapeutics Market Forecast (2010-2018) - Japan 31

3.17 Drivers and Barriers for Systemic Lupus Erythematosus 32

3.17.1 Drivers for the Systemic Lupus Erythematosus Therapeutics Market 32

3.17.2 Barriers for the Systemic Lupus Erythematosus Therapeutics Market 32

3.18 Opportunity and Unmet Need 33

3.19 Key Takeaway 33

4 Systemic Lupus Erythematosus Therapeutics Market - Competitive Assessment 34

4.1 Overview 34

4.1.1 Strategic Competitor Assessment 34

4.2 Product Profiles for the Major Products in Systemic Lupus Erythematosus 35

4.2.1 Targeted Drug 35

4.2.2 Immunosuppressants 36

4.2.3 Corticosteroids 36

4.3 Key Takeaway 36

5 Systemic Lupus Erythematosus Therapeutics - Pipeline Assessment 37

5.1 Overview 37

5.2 Strategic Pipeline Assessment 37

5.3 Pipeline Analysis by Phase of Development 38

5.3.1 Systemic Lupus Erythematosus Therapeutics - Phase III Pipeline 38

5.3.2 Systemic Lupus Erythematosus Therapeutics - Phase II Pipeline 39

5.3.3 Systemic Lupus Erythematosus Therapeutics - Phase I/II Pipeline 39

5.3.4 Systemic Lupus Erythematosus Therapeutics - Phase I Pipeline 39

5.3.5 Systemic Lupus Erythematosus Therapeutics - Preclinical Pipeline 40

5.3.6 Systemic Lupus Erythematosus Therapeutics - Discovery Pipeline 40

5.4 Systemic Lupus Erythematosus Therapeutics - Pipeline by Mechanism of Action 41

5.5 Systemic Lupus Erythematosus Therapeutics - Other Promising Mechanisms of Action 42

5.6 Technology Trends Analytic Framework 43

5.7 Systemic Lupus Erythematosus Therapeutics - Promising Drugs in Clinical Development 45

5.8 Molecule Profile for Promising Drugs under Clinical Development 46

5.8.1 Atacicept 46

5.8.2 Epratuzumab 47

5.8.3 LY2127399 48

5.8.4 Orencia 49

5.9 Key Takeaway 49

6 Systemic Lupus Erythematosus Therapeutics - Clinical Trial Mapping 50

6.1 Clinical Trials by Region/Country (US, EU5 and Japan) 50

6.2 Clinical Trials by Phase 51

6.3 Clinical Trials by Trial Status 52

6.4 Prominent Sponsors 53

6.5 Top Sponsors Participating in Systemic Lupus Erythematosus Therapeutics Clinical Trials 55

7 Systemic Lupus Erythematosus Therapeutics - Strategic Assessment 57

7.1 Key Events Impacting the Future Market 57

7.2 Future Market Competition Scenario 58

8 Systemic Lupus Erythematosus Therapeutics - Future Players 59

8.1 Introduction 59

8.2 Company Profiles 60

8.2.1 Human Genome Sciences 60

8.2.2 GlaxoSmithKline PLC 61

8.2.3 Merck KGaA/Merck Sereno 63

8.2.4 Eli-Lilly and Co. Ltd. 64

8.2.5 Immunomedics (Innovator)/UCB Inc. (Licensee) 65

8.2.6 Bristol Myers Squibb 67

8.3 Other Companies in the Systemic Lupus Erythematosus Market, 2011 69

9 Systemic Lupus Erythematosus Therapeutics - Licensing and Partnership Deals 71

10 Systemic Lupus Erythematosus Therapeutics - Appendix 78

10.1 Market Definitions 78

10.2 Abbreviations 78

10.3 Methodology 80

10.3.1 Coverage 80

10.3.2 Secondary Research 80

10.3.3 Forecasting 81

10.3.4 Primary Research 83

10.3.5 Expert Panel Validation 83

10.4 Contact Us 83

10.5 Disclaimer 83

10.6 Bibliography 84

List of Tables

Table 1: Prevalence of Systemic Lupus Erythematosus in Major Markets in 2011 7

Table 2: Female-to-Male Ratio of Systemic Lupus Erythematosus 7

Table 3: Systemic Lupus Erythematosus Therapeutics Market, Global, Revenue ($m), 2005-2010 13

Table 4: Systemic Lupus Erythematosus Therapeutics Market, Global, Market Forecast ($m), 2010-2018 15

Table 5: Systemic Lupus Erythematosus Therapeutics Market, The US, Revenue($m), 2005-2010 17

Table 6: Systemic Lupus Erythematosus Therapeutics Market, the US, Market Forecast ($m), 2010-2018 18

Table 7: Systemic Lupus Erythematosus Therapeutics Market, the UK, Revenue ($m), 2005-2010 19

Table 8: Systemic Lupus Erythematosus Therapeutics Market, the UK, Market Forecast ($m), 2010-2018 20

Table 9: Systemic Lupus Erythematosus Therapeutics Market, France, Revenue ($m), 2005-2010 21

Table 10: Systemic Lupus Erythematosus Therapeutics Market, France, Market Forecast ($m), 2010-2018 22

Table 11: Systemic Lupus Erythematosus Therapeutics Market, Germany, Revenue ($m), 2005-2010 23

Table 12: Systemic Lupus Erythematosus Therapeutics Market, Germany, Market Forecast ($m),2010-2018 24

Table 13: Systemic Lupus Erythematosus Therapeutics Market, Italy, Revenue ($m), 2005-2010 25

Table 14: Systemic Lupus Erythematosus Therapeutics Market, Italy, Market Forecast ($m), 2010-2018 26

Table 15: Systemic Lupus Erythematosus Therapeutics Market, Spain, Revenue ($m), 2005-2010 28

Table 16: Systemic Lupus Erythematosus Therapeutics Market, Spain, Market Forecast ($m), 2010-2018 29

Table 17: Systemic Lupus Erythematosus Therapeutics Market, Japan, Revenue ($m), 2005-2010 30

Table 18: Systemic Lupus Erythematosus Therapeutics Market, Japan, Market Forecast ($m), 2010-2018 31

Table 19: Efficacy Results of Benlysta Versus Placebo 35

Table 20: Systemic Lupus Erythematosus Therapeutics - Phase III Pipeline, 2011 38

Table 21: Systemic Lupus Erythematosus Therapeutics - Phase II Pipeline, 2011 39

Table 22: Systemic Lupus Erythematosus Therapeutics - Phase I/II Pipeline, 2011 39

Table 23: Systemic Lupus Erythematosus Therapeutics - Phase I Pipeline, 2011 39

Table 24: Systemic Lupus Erythematosus Therapeutics - Preclinical Pipeline, 2011 40

Table 25: Systemic Lupus Erythematosus Therapeutics - Discovery Pipeline, 2011 40

Table 26: Systemic Lupus Erythematosus Therapeutics - Other Promising Mechanisms of Actions 42

Table 27: Systemic Lupus Erythematosus Therapeutics - Promising Drugs in Clinical Development 45

Table 28: Efficacy of Epratuzumab 47

Table 29: Disease Severity at Baseline 47

Table 30: Severe (BILAG A) AdverseEffects of Epratuzumab 48

Table 31: Systemic Lupus Erythematosus Therapeutics - Clinical Mapping by Region/Country, 2011 50

Table 32: Systemic Lupus Erythematosus Therapeutics - Clinical Mapping by Phase, 2011 51

Table 33: Systemic Lupus Erythematosus Therapeutics - Clinical Mapping by Trial Status, 2011 52

Table 34: Systemic Lupus Erythematosus Therapeutics - Clinical Mapping by Overall Sponsors, 2011 53

Table 35: Systemic Lupus Erythematosus Therapeutics - Clinical Mapping by Prominent Sponsors, 2011 54

Table 36: Systemic Lupus Erythematosus Therapeutics - Clinical Mapping by Top Sponsors, 2011 56

Table 37: Human Genome Sciences - Pipeline Products, 2011 61

Table 38: GlaxoSmithKline PLC - Pipeline Products, 2011 63

Table 39: Merck KGaA / Merck Sereno - Pipeline Products, 2011 64

Table 40: Merck KGaA/Merck Sereno - Systemic Lupus Erythematosus Pipeline Product, 2011 64

Table 41: Eli Lilly and Co. Ltd - Pipeline Products, 2011 65

Table 42: Eli-Lilly and Co. Ltd - Systemic Lupus Erythematosus Pipeline Product, 2011 65

Table 43: Immunomedics Inc. - Pipeline Products, 2011 66

Table 44: Immunomedics Inc. - Systemic Lupus Erythematosus Pipeline Product, 2011 67

Table 45: Bristol Myers Squibb - Pipeline Product, 2011 68

Table 46: Bristol Myers Squibb - Systemic Lupus Erythematosus Pipeline Product, 2011 68

Table 47: Systemic Lupus Erythematosus Therapeutics - Future Players, 2011 69

Table 48: Systemic Lupus Erythematosus Therapeutics, Global, Deals 71

List of Figures

Figure 1: Treatment Algorithm of Systemic Lupus Erythematosus 10

Figure 2: Systemic Lupus Erythematosus Therapeutics Market, Global, Revenue ($m), 2005-2010 13

Figure 3: Systemic Lupus Erythematosus Therapeutics, Market Share (%), 2010 14

Figure 4: Systemic Lupus Erythematosus Therapeutics Market, Global, Market Forecast ($m), 2010-2018 15

Figure 5: Systemic Lupus Erythematosus Therapeutics, Market Share (%), 2018 16

Figure 6: Systemic Lupus Erythematosus Therapeutics Market, The US, Revenue ($m), 2005-2010 17

Figure 7: Systemic Lupus Erythematosus Therapeutics Market, the US, Market Forecast ($m), 2010-2018 18

Figure 8: Systemic Lupus Erythematosus Therapeutics Market, the UK, Revenue ($m), 2005-2010 19

Figure 9: Systemic Lupus Erythematosus Therapeutics Market, the UK, Market Forecast ($m), 2010-2018 20

Figure 10: Systemic Lupus Erythematosus Therapeutics Market, France, Revenue ($m), 2005-2010 21

Figure 11: Systemic Lupus Erythematosus Therapeutics Market, France, Market Forecast ($m), 2010-2018 22

Figure 12: Systemic Lupus Erythematosus Therapeutics Market, Germany, Revenue ($m), 2005-2010 23

Figure 13: Systemic Lupus Erythematosus Therapeutics Market, Germany, Market Forecast ($m), 2010-2018 24

Figure 14: Systemic Lupus Erythematosus Therapeutics Market, Italy, Revenue ($m), 2005-2010 25

Figure 15: Systemic Lupus Erythematosus Therapeutics Market, Italy, Market Forecast ($m), 2010-2018 26

Figure 16: Systemic Lupus Erythematosus Therapeutics Market, Spain, Revenue ($m), 2005-2010 28

Figure 17: Systemic Lupus Erythematosus Therapeutics Market, Spain, Market Forecast ($m), 2010-2018 29

Figure 18: Systemic Lupus Erythematosus Therapeutics Market, Japan, Revenue ($m), 2005-2010 30

Figure 19: Systemic Lupus Erythematosus Therapeutics Market, Japan, Market Forecast ($m), 2010-2018 31

Figure 20: Opportunity and Unmet Need in Systemic Lupus Erythematosus Therapeutics Market, 2011 33

Figure 21: Strategic Competitor Assessment of Systemic Lupus Erythematosus Therapeutics Market, 2011 34

Figure 22: Systemic Lupus Erythematosus Therapeutics Pipeline by Phase of Clinical Development, 2011 38

Figure 23: Systemic Lupus Erythematosus Therapeutics - Clinical Pipeline by Mechanism of Action, 2011 41

Figure 24: Technology Trends Analytic Framework of the Systemic Lupus Erythematosus Therapeutics Pipeline, 2011 43

Figure 25: Technology Trends Analytic Framework of the Systemic Lupus Erythematosus Therapeutics Pipeline - Description, 2011 44

Figure 26: Systemic Lupus Erythematosus Therapeutics - Clinical Mapping by Region/Country, 2011 50

Figure 27: Systemic Lupus Erythematosus Therapeutics - Clinical Mapping by Phase, 2011 51

Figure 28: Systemic Lupus Erythematosus Therapeutics - Clinical Mapping by Trial Status, 2011 52

Figure 29: Systemic Lupus Erythematosus Therapeutics - Clinical Mapping by Overall Sponsors, 2011 53

Figure 30: Systemic Lupus Erythematosus Therapeutics - Clinical Mapping by Prominent Sponsors, 2011 54

Figure 31: Systemic Lupus Erythematosus Therapeutics - Clinical Mapping by Top Sponsors, 2011 55

Figure 32: Systemic Lupus Erythematosus Therapeutics - Drivers and Barriers, 2011 57

Figure 33: Systemic Lupus Erythematosus Therapeutics - Implications for Future Market Competition, 2011 58

Figure 34: Systemic Lupus Erythematosus Therapeutics - Clinical Pipeline by Company, 2011 59

Figure 35: GlobalData Market Forecasting Model 82

Companies Mentioned

Human Genome Sciences

GlaxoSmithKline PLC

Merck KGaA/Merck Sereno

Eli-Lilly and Co. Ltd.

Immunomedics (Innovator)/UCB Inc. (Licensee)

Bristol Myers Squibb

To order this report:

Pathology Industry: Systemic Lupus Erythematosus Therapeutics (SLE) - Pipeline Assessment and Market Forecasts to 2018

Pathology Business News

More  Industry Analysis and Insights

Nicolas Bombourg
Reportlinker
Email: nbo@reportlinker.com
US: (805)652-2626
Intl: +1 805-652-2626


'/>"/>
SOURCE Reportlinker
Copyright©2010 PR Newswire.
All rights reserved


Related biology technology :

1. deCODE Announces Agreement With Pfizer to Search for Variants in the Human Genome That Confer Risk of Systemic Lupus Erythematosis
2. Pevions Therapeutic Candida Vaccine Shows Robust Systemic and Mucosal Immunogenicity, While Epidemiological Survey Confirms Excellent Market Potential
3. Sangamo BioSciences Announces Data Presentation of First In Vivo Demonstration of ZFN-mediated Gene Correction Via Systemic Delivery at American Society for Hematology Meeting
4. Biologic Agents Will Drive the Systemic Lupus Erythematosus Drug Market to More Than Quadruple to Nearly $2 Billion in 2018
5. Human Genome Sciences to Host July 20 Conference Call to Discuss Top-Line Phase 3 Results for Benlysta(TM) (Formerly Lymphostat-B(R)) in Systemic Lupus Erythematosus
6. Human Genome Sciences Reports Positive Long-Term Data for BENLYSTA(TM) (Formerly LymphoStat-B(R)) in Patients With Active Systemic Lupus Erythematosus
7. Trubion Pharmaceuticals, Inc. Announces Initiation of Phase 1 Study of SBI-087 for the Treatment of Systemic Lupus Erythematosus (SLE)
8. Anacor Achieves Milestone from GSK for Boron-Based Systemic Antibacterial Product Candidate
9. Lupus Research Institute: Benlysta(TM) Trial Results in an Historic Research Breakthrough and Victory for People With Lupus
10. Promise of a New Lupus Treatment Is a Groundbreaking Achievement
11. Influenza Vaccines Therapeutics - Pipeline Assessment and Market Forecasts to 2018
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... , Feb. 10, 2016 NX Prenatal ... its proprietary NeXosome® technology for early warning of ... its most recent study by Dr. Thomas ... the Society for Maternal Fetal Medicine,s (SMFM) annual meeting ... 1-6 th , 2016.  The presentation reported initial ...
(Date:2/10/2016)... 10, 2016  Matchbook, Inc., a company specializing ... biotech companies, announced today the appointment of ... Jim brings nearly 25 years of experience in ... spent nearly two decades in executive level roles ... at Genzyme and, most recently headed global logistics ...
(Date:2/10/2016)... ... February 10, 2016 , ... PatientCrossroads announces that ... secure online PatientCrossroads platform, has exceeded both its one-year and overall recruitment goals ... study, which seeks to advance understanding of the hereditary risks for certain kinds ...
(Date:2/9/2016)... ... February 09, 2016 , ... With a presidential election in ... Care Business Conference will bring together over 500 top healthcare leaders for a night ... transformation. The conference, organized by MBA students of the University of Pennsylvania’s Wharton School, ...
Breaking Biology Technology:
(Date:2/3/2016)... , Feb. 3, 2016 ... the addition of the "Emotion Detection ... Machine Learning, and Others), Software Tools (Facial ... Areas, End Users,and Regions - Global forecast ... --> http://www.researchandmarkets.com/research/d8zjcd/emotion_detection ) has ...
(Date:2/2/2016)... Va. , Feb. 2, 2016   ... award from the U.S. Army Research Office and ... the range and sensitivity of the company,s ... Past Accounting Mission and, more generally, defense-related DNA ... DNA phenotyping capabilities (predicting appearance and ancestry from ...
(Date:1/28/2016)... 2016 Synaptics (NASDAQ: SYNA ), a leading developer ... quarter ended December 31, 2015. --> ... 2016 increased 2 percent compared to the comparable quarter last year ... 2016 was $35.0 million, or $0.93 per diluted share. ... the first quarter of fiscal 2016 grew 9 percent over the ...
Breaking Biology News(10 mins):